Add to ORKGItem does not contain fulltextThe incidence of endometrial carcinoma is rising and the patients with distant metastases have a poor prognosis, especially when progression of disease occurs after systemic treatment with hormonal therapy or chemotherapy. Pazopanib, a multi-targeted inhibitor of several oncogenic receptor tyrosine kinases, has been investigated in patients with chemotherapy-resistant endometrial carcinoma or patients for whom chemotherapy is contraindicated. In this report we will describe a spectacular response to pazopanib in a patient with recurrent metastatic endometrial carcinoma
Patients with metastatic or recurrent endometrial cancer (EC) not suitable for surgery and/or radiot...
Patients with metastatic or recurrent endometrial cancer (EC) not suitable for surgery and/or radiot...
There is a medical need for new drugs in patients with BRAF wild-type metastatic melanoma. Pazopanib...
The incidence of endometrial carcinoma is rising and the patients with distant metastases have a poo...
The incidence of endometrial carcinoma is rising and the patients with distant metastases have a poo...
Abstract Background Pazopanib is an oral tyrosine kinase inhibitor registered for metastatic renal c...
pazopanib in breast cancer. The content of this article has been reviewed by independent peer review...
can be determined for recommended treatment options. h th dia of the malignant cells, with some or a...
Patients with primary metastatic/recurrent endometrial cancer have poor prognosis and available ther...
The current standard of treatment for patients with metastatic kidney cancer is targeted therapy, an...
Pazopanib is an oral multitargeted tyrozine kinase inhibitor that is used in advanced renal cancer i...
Patients with metastatic or recurrent endometrial cancer (EC) not suitable for surgery and/or radiot...
Uterine endometrial cancer is one of the most common gynecological malignancies worldwide. With rela...
Pazopanib (Votrient®) is an oral small-molecule multi-kinase inhibitor that predominantly inhibits v...
Item does not contain fulltextBACKGROUND: Pazopanib, a multitargeted tyrosine kinase inhibitor, has ...
Patients with metastatic or recurrent endometrial cancer (EC) not suitable for surgery and/or radiot...
Patients with metastatic or recurrent endometrial cancer (EC) not suitable for surgery and/or radiot...
There is a medical need for new drugs in patients with BRAF wild-type metastatic melanoma. Pazopanib...
The incidence of endometrial carcinoma is rising and the patients with distant metastases have a poo...
The incidence of endometrial carcinoma is rising and the patients with distant metastases have a poo...
Abstract Background Pazopanib is an oral tyrosine kinase inhibitor registered for metastatic renal c...
pazopanib in breast cancer. The content of this article has been reviewed by independent peer review...
can be determined for recommended treatment options. h th dia of the malignant cells, with some or a...
Patients with primary metastatic/recurrent endometrial cancer have poor prognosis and available ther...
The current standard of treatment for patients with metastatic kidney cancer is targeted therapy, an...
Pazopanib is an oral multitargeted tyrozine kinase inhibitor that is used in advanced renal cancer i...
Patients with metastatic or recurrent endometrial cancer (EC) not suitable for surgery and/or radiot...
Uterine endometrial cancer is one of the most common gynecological malignancies worldwide. With rela...
Pazopanib (Votrient®) is an oral small-molecule multi-kinase inhibitor that predominantly inhibits v...
Item does not contain fulltextBACKGROUND: Pazopanib, a multitargeted tyrosine kinase inhibitor, has ...
Patients with metastatic or recurrent endometrial cancer (EC) not suitable for surgery and/or radiot...
Patients with metastatic or recurrent endometrial cancer (EC) not suitable for surgery and/or radiot...
There is a medical need for new drugs in patients with BRAF wild-type metastatic melanoma. Pazopanib...